WCA
ALXN

Windsor Creek Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Windsor Creek Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,345
Closed -$578 – 213
2019
Q4 		$578 Hold
5,345
– – 0.15% 94
2019
Q3 		$523K Buy
5,345
+345
+7% +$38.9K 0.13% 106
2019
Q2 		$655K Sell
5,000
-3,700
-43% -$477K 0.18% 95
2019
Q1 		$1.18M Sell
8,700
-700
-7% -$87K 0.32% 75
2018
Q4 		$915K Buy
+9,400
New +$1.11M 0.29% 72

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Windsor Creek Advisors's ALXN Position: Q1 2020 in Review

Windsor Creek Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2020, closing a stake of 5,345 shares — an estimated $578 sold.

Windsor Creek Advisors first reported a position in ALXN in Q4 2018 and held it in 5 quarters. The position peaked at $1.18M in Q1 2019. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Windsor Creek Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 5,345 Alexion Pharmaceuticals shares in Q1 2020, an estimated $578.
  • Windsor Creek Advisors first reported a position in Alexion Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • Windsor Creek Advisors's Alexion Pharmaceuticals position peaked at $1.18M in Q1 2019.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.